Summary of project PR001833
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001833. The data can be accessed directly via it's Project DOI: 10.21228/M8SB0G This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR001833 |
| Project DOI: | doi: 10.21228/M8SB0G |
| Project Title: | Targeted metabolomics in severe asthmatic patients treated with biologics. |
| Project Type: | Targeted MS analysis |
| Project Summary: | Severe asthmatic patients prescribed either Mepolizumab or Omalizumab were followed during treatment, and serum samples were collected before treatment (T0), and both at 6 (T1) and 18 months (T2) after starting biological treatment. Treatment monitoring was performed by the analysis of a set of inflammatory metabolites using targeted metabolomics. |
| Institute: | CEMBIO |
| Last Name: | Contreras |
| First Name: | Nuria |
| Address: | Urb. Montepríncipe s/n, Ctra. Boadilla del Monte km 5.3, Madrid 28668, Spain |
| Email: | nuria.contrerasgomez1@ceu.es |
| Phone: | +3491372470014750 |
Summary of all studies in project PR001833
| Study ID | Study Title | Species | Institute | Analysis (* : Contains Untargted data) |
Release Date | Version | Samples | Download (* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST002948 | Multi-omics Approach Reveals a Specific Profile in Severe Asthmatic Patients Treated with Mepolizumab or Omalizumab | Homo sapiens | CEMBIO | MS | 2025-01-20 | 1 | 162 | Uploaded data (153.3M)* |
